- Reaction score
- 188
Samumed Sm04554 Results Normalized To Baseline
- Thread starter hypetraintime
- Start date
Wait what? This company rebranded itself and changed it's entire mission/target area with no press release? Uhhh
@pegasus2 You win this one. Even if the drug has clinically significant results this move is nothing but incredibly shady
Nothing actually changes with the drug obviously, but the argument against this company was that it was incredibly shady. This is an incredibly shady way to pivot the company, that press release doesn't even say why they changed names/direction or that they used to be Samumed. You can't find "Samumed" anywhere in that release. They also mention their entire pipeline except SM04554, which is closest to market. If it was about to drop impressive study results would be 100% listed there.
If I was an analyst covering private companies and I was following Samumed, this would be the largest red flag possible. There is nothing wrong with the name change in itself, but when companies are pivoting and don't do it in a PR friendly manor it's almost always a sign of large scale failures that they are hoping you don't notice.
Also, shifting to mRNA right as the hype is centered around this new emerging medical direction is the same thing as kodak camera's adding "blockchain" to their name and their stock going up 1000% overnight. It's a branding move in reaction to trying to generate investment.
No cope here, I thought the top-line data would have been out a month or two ago. Longer it went the more it was obvious. This move basically seals the deal.
And not even mention it in their statement about the pipeline in the press release?
True. They were supposed to have cured all the diseases they targeted.
As someone who doesn’t know how SM0554 actually works, can somebody explain to me how could a product like this not be profitable to them if, even though the regrowth wasn’t the greatest, seemed like it offered at least maintenance without sides? I mean, wouldn’t that be great in conjunction with a hair transplant?
Probably because it wont offer maintenance without sides. I've long said the same thing. If you give people another treatment option that's above baseline 1+ year up, people will still use it when the alternatives are so sparingly thin. If this drug offered 10-20% increase in density at 1 year it would have been a success imo, but it looks like it missed even that target.
Exactly.
They've gotten away with everything so far. Their story isn't over yet.
The renaming looks like a typical brand-laundering job. When a crooked used car dealer's reputation & legal liabilites become too much of a problem, he doesn't turn honest. He doesn't quit the business. He just moves to a different location and reopens with a new name.
Here we go; CEO Steps down, SM data in 4-6 weeks but the company predicts the OA drug program to be the first marketed, and it's phase 3 read out isnt until Q4.
endpts.com
Osman Kibar lays down his hand at Samumed, stepping away from CEO role as his once-heralded anti-aging biotech rebrands
Samumed made quite the entrance back in 2016, when it launched with some anti-aging programs and a whopping $12 billion valuation. That level of fanfare was nowhere to be found on Thursday, when the company added another $120 million to its coffers and quietly changed its name to Biosplice...
endpts.com
Last edited:
- Reaction score
- 70
Yeah they have nothing. They wouldn't communicate it this way if it looked promising. They didn't mention it in the press release, they stear away in this article. I wouldn't keep my hopes up. But at least they tried which is nice enough.
Yeah, I agree there. It might not be a total dud but it's not impressive, that's for sure.